Yes, use topical corticosteroid eye drops for herpes zoster ophthalmicus with ocular inflammation, but only in combination with systemic antiviral therapy.
In patients with HZO who develop ocular inflammation (keratitis, uveitis, iritis), topical corticosteroids should be used alongside oral antivirals to control inflammation and prevent vision-threatening complications. 1
Treatment Algorithm for HZO with Ocular Inflammation
First-Line Systemic Antiviral Therapy (Mandatory)
All patients with HZO and ocular inflammation require oral antivirals 1:
- Acyclovir 800 mg five times daily for 7 days, OR
- Valacyclovir 1000 mg every 8 hours for 7 days, OR
- Famciclovir 500 mg three times daily for 7 days
Topical Corticosteroid Therapy (When Inflammation Present)
When ocular inflammation develops (keratitis, stromal disease, iritis/uveitis), add topical corticosteroids 1:
- Use the minimum effective dose to control inflammation
- Prefer low-penetration steroids (fluorometholone or loteprednol) to minimize IOP elevation and cataract risk
- Taper slowly once inflammation is controlled
- Continue regular monitoring of IOP and visual acuity
Critical Distinction: VZV vs HSV
This recommendation applies specifically to varicella zoster virus (VZV), not herpes simplex virus (HSV). The guideline explicitly states that topical corticosteroids potentiate HSV epithelial infections and should be avoided in HSV conjunctivitis 1. Do not confuse these two viral entities—they require opposite approaches regarding topical steroids.
Evidence Supporting Combined Therapy
The 2024 Conjunctivitis Preferred Practice Pattern guideline clearly indicates that VZV conjunctivitis can be associated with multiple forms of ocular disease including keratitis, iritis/uveitis, and secondary glaucoma 1. While topical antivirals alone have not been shown helpful for VZV, the combination approach addresses both viral replication systemically and local inflammation.
Older comparative studies support this approach. A 1991 double-masked trial found that combined acyclovir and steroid therapy was superior to either agent alone, with topical acyclovir alone being insufficient for severe ocular inflammation, while steroids alone tended to require prolonged treatment and caused more rebound inflammation 2. Another 1983 study comparing topical acyclovir with steroids found acyclovir superior in terms of treatment duration (75 vs 280 days) with no recurrences, versus a 63% recurrence rate in the steroid-only group 3.
However, a 1991 prospective trial demonstrated that systemic acyclovir resulted in quick and complete resolution of ocular inflammation in all patients, while topical treatment alone led to chronic ocular inflammation in 40% of cases 4. This underscores that systemic antivirals are the foundation of therapy.
Long-Term Suppressive Therapy Consideration
The most recent high-quality evidence comes from the 2025 ZEDS trial 5, which evaluated suppressive valacyclovir (1000 mg daily) for 12 months in patients with history of HZO. While the primary endpoint at 12 months did not reach statistical significance (HR 0.77, P=0.09), the 18-month secondary endpoint showed significant benefit (HR 0.73, P=0.03), with reduced multiple episodes of keratitis or iritis at both timepoints. This supports consideration of 1 year of suppressive valacyclovir in patients with established HZO and recurrent inflammation.
Monitoring Requirements
Patients on topical corticosteroids require close follow-up 1:
- Regular measurement of IOP (risk of steroid-induced glaucoma)
- Pupillary dilation to evaluate for cataract formation
- Visual acuity monitoring
- Slit-lamp biomicroscopy to assess inflammation control
Common Pitfalls to Avoid
- Do not withhold steroids in VZV due to concerns about HSV—these are different viruses with different pathophysiology
- Never use topical steroids without concurrent systemic antivirals in HZO
- Do not use high-penetration steroids (like prednisolone acetate) as first choice—prefer fluorometholone or loteprednol to reduce IOP/cataract risk
- Avoid abrupt discontinuation—taper slowly to prevent rebound inflammation
- Do not rely on topical antivirals alone—they are ineffective for VZV 1, 4
Special Populations
For immunocompromised patients, more aggressive treatment may be needed with dose adjustments based on clinical response 1. Exercise caution with systemic antivirals in patients with impaired renal clearance and adjust dosing accordingly 1.